news aktuell GmbH

ELATEC Strengthens Global Presence with Regional Hub in Dubai

Dela

Puchheim, January 23, 2025 – ELATEC, a leading global provider of user authentication and identification solutions, is beginning 2025 with a significant step forward in its global expansion strategy: the launch of its new office in Dubai. Operating under the name ELATEC Middle East Trading FZE, this new location will serve as a dedicated hub to support the company’s growing customer base and partners across the Middle East. The operations, led by Managing Director Carsten Hoersch, are set to drive innovative, secure, and tailored access control solutions in the region.

A Strategic Milestone in the Middle East

Gerhard Burits, CEO of the ELATEC Group, emphasized the strategic importance of this expansion: “Our new presence in the GCC (Gulf Cooperation Council) demonstrates our commitment to strengthening relationships with regional partners and addressing market-specific needs. This move aligns seamlessly with our mission to provide secure, flexible, and future-ready solutions. The Dubai office is a vital addition to our global network and will act as a springboard for further growth in this dynamic region.”

The Middle East is a region of rapid development and innovation, and ELATEC’s new office demonstrates the company’s commitment to identification technologies that empower customers to deliver advanced solutions to their markets.

Driving Localized Solutions and Collaboration

With the launch of ELATEC Middle East Trading FZE, the company aims to foster closer collaboration with OEMs, system integrators, distributors, and other local stakeholders. This local presence allows ELATEC to address specific market demands and offer enhanced customer support and faster response times.

Carsten Hoersch, Managing Director of ELATEC Middle East Trading FZE, shared his vision for the new office: “Establishing a local hub in the United Arab Emirates enables us to work hand-in-hand with our partners and customers, developing innovative solutions that add real value to their businesses. Our focus is on building trust, delivering top-tier support, and driving advancements in secure and seamless access technology tailored to the region’s unique requirements.”

About ELATEC

ELATEC is a leading global provider of user authentication and identification solutions. Together with its global partners, the company develops innovative and future-proof access systems. Combining pioneering universal readers, advanced authentication software, and world-class service and support, ELATEC delivers secure, flexible solutions that transform access management—from physical access control to digital access management, machine authentication, secure printing, EV charging, and more. ELATEC’s comprehensive portfolio of multi-technology readers supports more than 60 transponder technologies (including LF and HF RFID, NFC, and BLE) and is remotely configurable and updatable, ensuring seamless interoperability and adaptability to evolving market needs. ELATEC collaborates with OEMs, integrators, and organizations to design customized access solutions that enhance security, improve user convenience, and simplify management. Founded in 1988 and headquartered in Munich, Germany, ELATEC is represented at 19 locations worldwide. For more information, visit www.elatec.com.

Suited Pictures (Copyright ELATEC): https://pixx.elatec.com/share/1737467969oJ4Vn0qvwbkLcf

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Följ news aktuell GmbH

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från news aktuell GmbH

Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 12:34:15 CET | Press Release

Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions

Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release

Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye